

Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry

Matthias Griese,¹ Elias Seidl,¹ Katrin Knoflach,¹ Julia Ley-Zaporozhan,² Birgit Kammer,² Ingrid Krueger-Stollfuss,² Simone Reu-Hofer,³ Nicolaus Schwerk,⁴ Julia Carlens,⁴ Martin Wetzke,⁴ Nagehan Emiralioglu,⁵ Nural Kiper,⁵ Florian Stehling,⁶ Joanna Lange,⁷ Katarzyna Krenke⁷

¹Hauner Children's Hospital, Ludwig Maximilian University, Munich, Germany; ²Department of Radiology, Pediatric Radiology, Ludwig Maximilian University, Munich, Germany; ³Pathological Institute, University of Wuerzburg, Wuerzburg, Germany; ⁴Clinic for Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; ⁵Department of Pediatric Pulmonology, Hacettepe University Faculty of Medicine, Ankara, Turkey; ⁶Department of Pediatrics III, University Duisburg-Essen, University Hospital Essen, Essen, Germany; ⁷Department of Pediatric Pneumology and Allergy, Medical University of Warsaw, Warsaw, Poland


BACKGROUND

- Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders¹
- There is some overlap with entities observed in adults but also many differences²
 - Many are exclusive to infants and children
 - Idiopathic pulmonary fibrosis is exclusive to adults
- There is little data on pulmonary fibrosis in chILD
- European chILD registry (chILD-EU; NCT02852928)³
 - International network of expert centres specialised in chILD
 - Cooperatively assesses and follows patients with chILD
 - Broad spectrum of patients are classified into disease categories¹

AIMS


- To assess the prevalence of fibrosis in lung biopsies from chILD-EU
- To correlate paediatric lung fibrosis with radiological findings

METHODS



RESULTS


PRESENCE OF FIBROSIS IN BIOPSIES




DISEASE CATEGORIES AND FIBROSIS IN BIOPSY

- Approximately half of the patients had conditions that primarily manifested during infancy, either surfactant dysfunction disorders or persistent tachypnoea of infancy (NEHI, an infant condition of undefined aetiology)
- Fibrosis was predominantly observed in disorders of the alveolar surfactant region, accounting for more than half of cases

Disease category	Proportion of chILD cases (%)	Proportion of fibrosis cases (%)
Alveolar surfactant region	26.7	64.4
Systemic disease processes	12.4	10.2
Exposures	15	8.5
Immunocompromised	4.8	5.1
RDS in mature neonate	1.8	3.4
Infant conditions of undefined aetiology	20.1	1.7
Lung vessels	8.3	1.7
Lung growth abnormalities	6.4	1.7
Diffuse developmental disorders	3.4	1.7
Lymphoid lesions	1.1	1.7



HISTOLOGY AND THE CORRESPONDING CT SCAN



CONCLUSIONS

- Features of fibrosis were present in about 40% of chILD cases with a diagnostic lung biopsy
- Concordance between biopsy- and CT-diagnosed fibrosis was lower than expected
- Further studies may help to evaluate the use of biopsy in the diagnosis of fibrosis in chILD



References

- Griese M, et al. Orphanet J Rare Dis 2015; 10:122;
- Glasser SW, et al. Pediatr Allergy Immunol Pulmonol 2010; 23:9–14;
- Griese M, et al. Thorax 2018; 73:231–239.

Abbreviations

chILD, childhood interstitial lung disease; chILD-EU, European chILD registry; CPI, chronic pneumonitis of infancy; CT, computed tomography; NEHI, neuroendocrine cell hyperplasia of infancy; RDS, respiratory distress syndrome.

Author disclosures

MG reports grants from Boehringer Ingelheim. JL-Z reports grants from Boehringer Ingelheim. ES, KKn, BK, IK-S, SR-H, NS, JC, MW, NE, NK, FS, JL and KKr have nothing to disclose.

Acknowledgements

This study was supported by Boehringer Ingelheim International GmbH (BI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for the development of this poster. Writing, editorial support and formatting assistance was provided by Darren Chow, of MediTech Media, UK, which was contracted and funded by BI. BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations.

